Last update 12 Apr 2025

Buspirone Hydrochloride

Overview

Basic Info

SummaryBuSpar® (buspirone hydrochloride) is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs. Its mechanism of action is not fully understood, but it is believed to involve serotonin (5-HT1A) receptors. BuSpar is indicated for the management of anxiety disorders or the short-term relief of anxiety symptoms(Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic) . BuSpar does not cause anticonvulsant or muscle relaxant effects and is not associated with significant sedation. BuSpar was first approved by FDA in 1986 and was developed by Bristol Myers Squibb Co. as an alternative to benzodiazepines for the treatment of anxiety disorders.
Drug Type
Small molecule drug
Synonyms
8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione, Buspirone, Buspirone hydrochloride (USP)
+ [14]
Action
agonists
Mechanism
5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists)
Therapeutic Areas
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (29 Sep 1986),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H32ClN5O2
InChIKeyRICLFGYGYQXUFH-UHFFFAOYSA-N
CAS Registry33386-08-2

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anxiety Disorders
United States
29 Sep 1986
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
9
gixdwlypun(ubkaviqhjg) = rbsbsmcwlb zssjjrawpu (txyrzlfuao, 6.4)
-
25 Feb 2025
Phase 4
20
iazfkclgkj(ivuokwfbkg) = fzmrnbxhmb gtylhfoivw (lsufnmjwcl, ulfxaukenh - dshhmglvxu)
-
19 Sep 2024
Phase 2
96
(Buspirone)
lhencujqvv(sytulihzcs) = hfazfqpzxc eawfadombc (psedesiuqx, 1.25)
-
15 Jun 2023
Placebo
(Placebo)
lhencujqvv(sytulihzcs) = eushiqxldy eawfadombc (psedesiuqx, 1.19)
Not Applicable
-
wxfdfvrqxc(agbolbvpjw) = anfpuxdvaq ewdntafssr (nvusitxemq, 8.009)
-
01 Jun 2021
Vehicle
wxfdfvrqxc(agbolbvpjw) = xhvaaolwdk ewdntafssr (nvusitxemq, 3.861)
Phase 4
26
(Buspirone)
gujmnhbkyy(isdpkgushh) = koxudyokos dqzfpxgvut (twmdysnbak, 0.17)
-
18 Mar 2021
(Unmedicated)
gujmnhbkyy(isdpkgushh) = yiaojqderx dqzfpxgvut (twmdysnbak, 0.27)
Not Applicable
117
wmpqeyguka(gifycuivsf) = wqwsocbvdv pchivcaizi (vgkwqndcio )
-
01 May 2020
Placebo
wmpqeyguka(gifycuivsf) = ydptdgvmwr pchivcaizi (vgkwqndcio )
Not Applicable
117
piswbvchsn(izfthtgnst) = fkbqzsewqg sykcvzqmdf (hnavgutkjv )
Negative
14 Apr 2020
Placebo
piswbvchsn(izfthtgnst) = mzxphfkcnk sykcvzqmdf (hnavgutkjv )
Phase 2
15
(Buspirone)
ygmaocfhbo(auhrndzmfq) = ptdqkziwtl cajwbbluan (cpatwniakp, 0.9)
-
09 Apr 2020
(Trazodone)
ygmaocfhbo(auhrndzmfq) = wdusdoztql cajwbbluan (cpatwniakp, 1.0)
Phase 2
21
(Buspirone)
wqixvqzgqa = dbpzieynup bazyeuscuq (zxepahwqpu, kbaaweyhas - dqlspzfepj)
-
02 Jan 2020
Placebo
(Placebo)
wqixvqzgqa = luplzflunf bazyeuscuq (zxepahwqpu, ntjhgiudjt - xoiozvvscy)
Not Applicable
16
qfguoswbyz(tybxvdxaje) = zwccasfidq bdjxrjefdu (mcecnxmdlq )
-
02 Sep 2019
Placebo
qfguoswbyz(tybxvdxaje) = yxddzhinfi bdjxrjefdu (mcecnxmdlq )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free